In the US, Simponi (golimumab systemic) is a member of the drug class TNF alfa inhibitors and is used to treat Ankylosing Spondylitis, Psoriatic Arthritis, Rheumatoid Arthritis, Spondyloarthritis and Ulcerative Colitis.
Ingredient matches for Simponi
Golimumab is reported as an ingredient of Simponi in the following countries:
- Croatia (Hrvatska)
- United Kingdom
- United States